{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:17:58Z","timestamp":1783023478464,"version":"3.54.6"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nursing Clinics of North America"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.cnur.2025.09.004","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T12:27:41Z","timestamp":1763987261000},"page":"81-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ketamine-Prazosin Combined Pharmacotherapy in Post-Traumatic Stress Disorder and Alcohol Use Disorder"],"prefix":"10.1016","volume":"61","author":[{"given":"Amanda","family":"Canada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cnur.2025.09.004_bib1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1176\/appi.ajp.22010071","article-title":"Project harmony: a meta-analysis with individual patient data on behavioral and pharmacologic trials for comorbid posttraumatic stress and alcohol or other drug use disorders","volume":"180","author":"Hien","year":"2023","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.cnur.2025.09.004_bib2","first-page":"714","article-title":"Psychotherapeutic and pharmacological treatments for comorbid posttraumatic stress disorder and alcohol use disorder: a review of the literature","volume":"31","author":"Petrakis","year":"2011","journal-title":"Clin Psychol Rev"},{"issue":"2","key":"10.1016\/j.cnur.2025.09.004_bib3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/acer.13297","article-title":"Posttraumatic stress disorder and alcohol use disorder: a critical review of pharmacologic treatments","volume":"41","author":"Petrakis","year":"2017","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"10.1016\/j.cnur.2025.09.004_bib4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1176\/appi.ajp.2020.20050596","article-title":"A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder","volume":"178","author":"Feder","year":"2021","journal-title":"Am J Psychiatry"},{"issue":"9","key":"10.1016\/j.cnur.2025.09.004_bib5","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1176\/appi.ajp.2013.12081133","article-title":"A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan","volume":"170","author":"Raskind","year":"2013","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.cnur.2025.09.004_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2022.114840","article-title":"An evidence-based approach to psychopharmacology for posttraumatic stress disorder (PTSD) - 2022 update","volume":"317","author":"Bajor","year":"2022","journal-title":"Psychiatry Res"},{"issue":"2","key":"10.1016\/j.cnur.2025.09.004_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1176\/appi.ajp.2019.19070684","article-title":"A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial","volume":"177","author":"Dakwar","year":"2020","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.cnur.2025.09.004_bib8","first-page":"1","article-title":"Safety and efficacy of ketamine for the treatment of patients with alcohol use disorder: a systematic review","author":"Rathore","year":"2025","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"10","key":"10.1016\/j.cnur.2025.09.004_bib9","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.2174\/1389450116666150506114108","article-title":"Targeting the noradrenergic system in posttraumatic stress disorder: a systematic review and meta-analysis of prazosin trials","volume":"16","author":"Berardis","year":"2015","journal-title":"Curr Drug Targets"},{"issue":"12","key":"10.1016\/j.cnur.2025.09.004_bib10","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1176\/appi.ajp.2018.17080913","article-title":"Double-blind randomized clinical trial of prazosin for alcohol use disorder","volume":"175","author":"Simpson","year":"2018","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.cnur.2025.09.004_bib11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.addbeh.2013.08.014","article-title":"Pharmacological treatment of comorbid PTSD and substance use disorder: recent progress","volume":"39","author":"Sofuoglu","year":"2014","journal-title":"Addict Behav"},{"issue":"2","key":"10.1016\/j.cnur.2025.09.004_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.35946\/arcr.v39.2.09","article-title":"Pharmacotherapy for co-occurring alcohol use disorder and post-traumatic stress disorder: targeting the opioidergic, noradrenergic, serotonergic, and GABAergic\/glutamatergic systems","volume":"39","author":"Verplaetse","year":"2018","journal-title":"Alcohol Res Curr Rev"},{"key":"10.1016\/j.cnur.2025.09.004_bib13","unstructured":"Food and Drug Administration. Ketalar. FDA Drug Label."},{"key":"10.1016\/j.cnur.2025.09.004_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2020.112631","article-title":"Ketamine\u2019s dose related multiple mechanisms of actions: dissociative anesthetic to rapid antidepressant","volume":"390","author":"Lavender","year":"2020","journal-title":"Behav Brain Res"},{"issue":"12","key":"10.1016\/j.cnur.2025.09.004_bib15","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.amjmed.2018.04.029","article-title":"Nonanesthetic effects of ketamine: a review article","volume":"131","author":"Eldufani","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.cnur.2025.09.004_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120152","article-title":"Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence","volume":"434","author":"Subramanian","year":"2022","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.cnur.2025.09.004_bib17","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol Rev"},{"issue":"13","key":"10.1016\/j.cnur.2025.09.004_bib18","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.3390\/molecules30132824","article-title":"Ketamine\u2014From an anesthetic to a psychiatric drug: mechanisms of action, clinical applications and potential risks","volume":"30","author":"Gibu\u0142a-Tar\u0142owska","year":"2025","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.cnur.2025.09.004_bib19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0022-3565(25)30914-6","article-title":"Alpha blocking action of the antihypertensive agent, prazosin","volume":"201","author":"Graham","year":"1977","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"10.1016\/j.cnur.2025.09.004_bib20","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1007\/s12031-020-01518-7","article-title":"Evaluation of the effect of prazosin treatment on \u03b1-2c adrenoceptor and apoptosis protein levels in the predator scent-induced rat model of post-traumatic stress disorder","volume":"70","author":"Aykac","year":"2020","journal-title":"J Mol Neurosci"},{"issue":"1","key":"10.1016\/j.cnur.2025.09.004_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0014-2999(92)90263-4","article-title":"Comparison of peripheral and central nervous system sympatholytic actions of prazosin using the cat nictitating membrane","volume":"211","author":"Koss","year":"1992","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"10.1016\/j.cnur.2025.09.004_bib22","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1440-1681.1997.tb02720.x","article-title":"Evidence for direct interaction of ketamine with \u03b1- and \u03b2 2 -adrenoceptors","volume":"24","author":"Bevan","year":"1997","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"7","key":"10.1016\/j.cnur.2025.09.004_bib23","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/0269881115573809","article-title":"Impact of subanesthetic doses of ketamine on AMPA-Mediated responses in rats: an in vivo electrophysiological study on monoaminergic and glutamatergic neurons","volume":"29","author":"El Iskandrani","year":"2015","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.cnur.2025.09.004_bib24","author":"Defense"},{"issue":"7","key":"10.1016\/j.cnur.2025.09.004_bib25","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1177\/10600280231199666","article-title":"The impact of ketamine for treatment of post-traumatic stress disorder: a systematic review with meta-analyses","volume":"58","author":"Sicignano","year":"2024","journal-title":"Ann Pharmacother"},{"issue":"12","key":"10.1016\/j.cnur.2025.09.004_bib26","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1177\/0271678X221116477","article-title":"Evidence for the beneficial effect of ketamine in the treatment of patients with post-traumatic stress disorder: a systematic review and meta-analysis","volume":"42","author":"Albuquerque","year":"2022","journal-title":"J Cerebr Blood Flow Metabol"},{"issue":"11","key":"10.1016\/j.cnur.2025.09.004_bib27","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/s41386-023-01606-3","article-title":"Long term structural and functional neural changes following a single infusion of ketamine in PTSD","volume":"48","author":"Duek","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"13","key":"10.1016\/j.cnur.2025.09.004_bib28","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41386-021-01104-4","article-title":"Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence","volume":"46","author":"Norbury","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.cnur.2025.09.004_bib29","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1507598","article-title":"Trial of prazosin for post-traumatic stress disorder in military veterans","volume":"378","author":"Raskind","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cnur.2025.09.004_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2025.111253","article-title":"Factors impacting prazosin efficacy for nightmares and insomnia in PTSD patients - a systematic review and meta-regression analysis","volume":"136","author":"Mendes","year":"2025","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.cnur.2025.09.004_bib31","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1017\/S1092852920001121","article-title":"Prazosin for treatment of post-traumatic stress disorder: a systematic review and meta-analysis","volume":"26","author":"Reist","year":"2021","journal-title":"CNS Spectr"},{"key":"10.1016\/j.cnur.2025.09.004_bib32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.genhosppsych.2015.10.007","article-title":"Prazosin for treating sleep disturbances in adults with posttraumatic stress disorder: a systematic review and meta-analysis of randomized controlled trials","volume":"39","author":"Khachatryan","year":"2016","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.cnur.2025.09.004_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1141836","article-title":"The therapeutic use and efficacy of ketamine in alcohol use disorder and alcohol withdrawal syndrome: a scoping review","volume":"14","author":"Goldfine","year":"2023","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.cnur.2025.09.004_bib34","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.neubiorev.2021.05.006","article-title":"Therapeutic potential of ketamine for alcohol use disorder","volume":"126","author":"Worrell","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.cnur.2025.09.004_bib35","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuropharm.2018.01.017","article-title":"Ketamine for the treatment of addiction: evidence and potential mechanisms","volume":"142","author":"Ivan Ezquerra-Romano","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.cnur.2025.09.004_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109606","article-title":"Efficacy of ketamine intervention to decrease alcohol use, cravings, and withdrawal symptoms in adults with problematic alcohol use or alcohol use disorder: a systematic review and comprehensive analysis of mechanism of actions","volume":"239","author":"Garel","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.cnur.2025.09.004_bib37","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2021.21030277","article-title":"Adjunctive ketamine with relapse prevention\u2013based psychological therapy in the treatment of alcohol use disorder","volume":"179","author":"Grabski","year":"2022","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.cnur.2025.09.004_bib38","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21f13980","article-title":"Prazosin for alcohol use disorder","volume":"82","author":"Andrade","year":"2021","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"10.1016\/j.cnur.2025.09.004_bib39","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1111\/acer.14378","article-title":"Effects of prazosin on provoked alcohol craving and autonomic and neuroendocrine response to stress in alcohol use disorder","volume":"44","author":"Milivojevic","year":"2020","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.cnur.2025.09.004_bib40","series-title":"Prazosin hydrochloride","year":"2025"},{"issue":"5","key":"10.1016\/j.cnur.2025.09.004_bib41","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/acer.12703","article-title":"A pilot trial of prazosin, an Alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder","volume":"39","author":"Simpson","year":"2015","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"10.1016\/j.cnur.2025.09.004_bib42","first-page":"5","article-title":"Nurse practitioners in primary care: current role and future challenges","volume":"16","author":"Fitzpatrick","year":"2020","journal-title":"J Nurse Pract"},{"issue":"2","key":"10.1016\/j.cnur.2025.09.004_bib43","first-page":"95","article-title":"Prescriptive authority and the nurse practitioner: the path forward","volume":"25","author":"Delaney","year":"2019","journal-title":"J Am Psychiatr Nurses Assoc"}],"container-title":["Nursing Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0029646525000726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0029646525000726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:37:34Z","timestamp":1783021054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0029646525000726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0029646525000726"],"URL":"https:\/\/doi.org\/10.1016\/j.cnur.2025.09.004","relation":{},"ISSN":["0029-6465"],"issn-type":[{"value":"0029-6465","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ketamine-Prazosin Combined Pharmacotherapy in Post-Traumatic Stress Disorder and Alcohol Use Disorder","name":"articletitle","label":"Article Title"},{"value":"Nursing Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cnur.2025.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}